樂觀
$7.55
情境價格
$11.810
-0.443 (-3.75%)收盤時
Neogen Corporation and subsidiaries are engaged in developing, manufacturing and marketing a diverse line of products and services dedicated to food and animal safety. The Company has developed comprehensive solutions spanning the Food Safety, Livestock, and Pet Health & Wellness markets. Its segments include Food Safety and Animal Safety. The Food Safety segment is primarily engaged in the development, production and marketing of diagnostic test kits and related products used by food producers and processors to detect harmful natural toxins, foodborne bacteria, allergens and levels of general sanitation. The Animal Safety segment is primarily engaged in the development, production and marketing of products dedicated to animal safety, including a complete line of consumable products marketed to veterinarians and animal health product distributors. This segment also provides genomic identification and related interpretive bioinformatic services.
Neogen Corp is a good buy right now due to its recent fiscal guidance upgrade, raising revenue expectations to between $885 million and $890 million, and a significant improvement in financial performance, including a net loss reduction to $11.3 million in Q4 from a $612.2 million loss last year. Additionally, the stock has shown a year-to-date increase of 69.29%, indicating strong momentum. However, the main risk is the recent FDA warning that caused a 7.22% drop in shares, highlighting product safety concerns.
Guggenheim
$14
2026-09-30
Guggenheim
2026-09-30
目標價
$14
Guggenheim
$12
2026-09-29
Guggenheim
2026-09-29
目標價
$12
Piper Sandler
$14
2026-08-26
Piper Sandler
2026-08-26
目標價
$14
Piper Sandler
$13
2026-08-03
Piper Sandler
2026-08-03
目標價
$13
Guggenheim
$12
2026-01-09
Guggenheim
2026-01-09
目標價
$12
情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

Neogen Unveils 2026 Investor Day Strategy for Growth

Neogen Shares Drop 7.22% Following FDA Warning on HYCOAT

Neogen Corp Raises Fiscal Guidance, Stock Jumps 11%

NEOG Shares Drop 7.22% Following FDA Warning on HYCOAT

Neogen Corporation Under Investigation for Securities Law Violations
Neogen Corporation and subsidiaries are engaged in developing, manufacturing and marketing a diverse line of products and services dedicated to food and animal safety. The Company has developed comprehensive solutions spanning the Food Safety, Livestock, and Pet Health & Wellness markets. Its segments include Food Safety and Animal Safety. The Food Safety segment is primarily engaged in the development, production and marketing of diagnostic test kits and related products used by food producers and processors to detect harmful natural toxins, foodborne bacteria, allergens and levels of general sanitation. The Animal Safety segment is primarily engaged in the development, production and marketing of products dedicated to animal safety, including a complete line of consumable products marketed to veterinarians and animal health product distributors. This segment also provides genomic identification and related interpretive bioinformatic services. It operates in the Healthcare sector (IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES industry).
Neogen Corp is a good buy right now due to its recent fiscal guidance upgrade, raising revenue expectations to between $885 million and $890 million, and a significant improvement in financial performance, including a net loss reduction to $11.3 million in Q4 from a $612.2 million loss last year. Additionally, the stock has shown a year-to-date increase of 69.29%, indicating strong momentum. However, the main risk is the recent FDA warning that caused a 7.22% drop in shares, highlighting product safety concerns.
7 analysts cover NEOG: 0 rate it Buy, 7 Hold and 0 Sell. The average price target is 8.17.
本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。